Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Trump, Canada Reach Gordie Howe Bridge Deal Ahead of July 27 Opening 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Gold Prices Slip as U.S.-Iran Conflict, Fed Rate Hike Bets Pressure Precious Metals 
US Stock Futures Steady as US-Iran Tensions and Fed Inflation Concerns Weigh on Markets 
Fed Chair Kevin Warsh Launches Task Forces to Overhaul U.S. Monetary Policy Framework 
Deutsche Bank Sees Global Capital Shifts Reshaping Long-Term U.S. Dollar Outlook 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
China Inflation Cools in June as Producer Prices Hit Four-Year High 
Japan Producer Inflation Hits 7.1% in June, Fueling BOJ Rate Hike Expectations 
Dollar Ends Week Higher as Yen Jumps on Japan Pension Fund Investment Plans 
Gold Prices Set for Weekly Loss as Iran Tensions and Fed Rate Outlook Weigh 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Bernstein Raises 2026 Nickel Price Forecast as Indonesia Tightens Supply 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Samsung Biologics and Samsung C&T are investing in Araris Switzerland-based biotech company. The former announced on Wednesday, April 12, that it would be joining in the series A funding round for the said Swiss firm.
Arais Biotech AG is a company that makes antibody-drug conjugate (ADC) technologies. This refers to a type of medicine formulated as a targeted therapy for the treatment of cancer.
Samsung Biologics is the contract manufacturing arm of the Samsung Group, and it has confirmed its participation in the funding round to secure a stake in the Swiss ADC company. As per The Korea Herald, it will be making its investments in Araris through Samsung Life Science Fund, which is being co-managed by Samsung Biologics and Samsung C&T.
The fund is said to be worth around KRW150 billion or $113 million, and it was set up in 2021 to support Samsung Biologics' bid to find new business opportunities in the global biotech industry.
It was said that the undisclosed amount of investment funds would be primarily used to back Araris in its works for the development of potential candidates for ADCs. The value of the fund was not shared with the public because of the agreements made between Samsung Biologics and Araris.
The South Korean biotech firm added that through this new investment, it is aiming to expand its ADC-related portfolio as well. It will also be able to actively participate in the production of ADC drugs through its partnership with Araris.
“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” Samsung Biologics’ president and chief executive officer, John Rim, said in a statement.
Araris Biotech’s CEO and co-founder, Philipp Spycher, Ph.D., added, “We are pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field and we look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”
